Regency Capital Management’s Charles River Laboratories CRL Stock Holding History

Regency Capital Management’s Portfolio CRL Stock Details CRL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2024 Q2	–	Sell	-17,930	Closed	-$4.86M	–	48
2024 Q1	$4.86M	Buy	17,930 +2,265	+14%	+$541K	3.09%	12
2023 Q4	$3.7M	Buy	+15,665	New	+$3.08M	2.49%	18
2022 Q1	–	Sell	-796	Closed	-$300K	–	113
2021 Q4	$300K	Sell	796 -1,126	-59%	-$437K	0.19%	57
2021 Q3	$793K	Sell	1,922 -3,914	-67%	-$1.63M	0.56%	39
2021 Q2	$2.16M	Buy	5,836 +700	+14%	+$234K	1.63%	19
2021 Q1	$1.49M	Buy	+5,136	New	+$1.43M	1.57%	24

Other funds holding CRL

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Kayne Anderson Rudnick Investment Management Los Angeles, California $34B AUM 6.31% 1-Year Est. Return

ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Allspring Global Investments Charlotte, North Carolina $59.7B AUM 29.08% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Meritage Group San Francisco, California $2.65B AUM 6.3% 1-Year Est. Return

SCA

Southpoint Capital Advisors New York $4.86B AUM 34.09% 1-Year Est. Return

EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return

Regency Capital Management's CRL Position: Q2 2024 in Review

Regency Capital Management sold out of Charles River Laboratories (CRL) in Q2 2024, closing a stake of 17,930 shares — an estimated $4.86M sold.

Regency Capital Management first reported a position in CRL in Q1 2021 and held it in 6 quarters. The position peaked at $4.86M in Q1 2024. 664 funds tracked by Wall St. Rank hold CRL as of Q2 2024.

Regency Capital Management reported no remaining Charles River Laboratories position as of Q2 2024 after selling out during the quarter.
Regency Capital Management sold 17,930 Charles River Laboratories shares in Q2 2024, an estimated $4.86M.
Regency Capital Management first reported a position in Charles River Laboratories in Q1 2021 and held it in 6 quarters.
Regency Capital Management's Charles River Laboratories position peaked at $4.86M in Q1 2024.
664 funds tracked by Wall St. Rank held Charles River Laboratories as of Q2 2024.

Based on Regency Capital Management's 13F filing for Q2 2024, filed 21 Aug 2024.